Update: Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial

MT Newswires Live

Yesterday

(Updates with the latest stock price movement in the headline and the first paragraph.)

Edgewise Therapeutics (EWTX) shares rose 20% in recent Wednesday trading after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.

The company said EDG-7500 was generally well tolerated with no clinically meaningful reductions in left ventricular ejection fraction and no cases of ejection fraction drops below 50%.

Edgewise Therapeutics said it remains on track to report a full 12-week readout from part D in Q2 2026 and plans to initiate a phase 3 trial in Q4 2026.

Hypertrophic cardiomyopathy is a form of genetic heart disease.

Price: 26.01, Change: +4.27, Percent Change: +19.61

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2593640382"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593640382\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593640382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-24 23:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593640382","market":"hk","top_or_hot":-1,"title":"Update: Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial","media":"MT Newswires Live","content":"<html><body><p> (Updates with the latest stock price movement in the headline and the first paragraph.)</p><p>Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) shares rose 20% in recent Wednesday trading after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.</p><p>The company said EDG-7500 was generally well tolerated with no clinically meaningful reductions in left ventricular ejection fraction and no cases of ejection fraction drops below 50%.</p><p>Edgewise Therapeutics said it remains on track to report a full 12-week readout from part D in Q2 2026 and plans to initiate a phase 3 trial in Q4 2026.</p><p>Hypertrophic cardiomyopathy is a form of genetic heart disease.</p><p>Price: 26.01, Change: +4.27, Percent Change: +19.61</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Update: Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUpdate: Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-24 23:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> (Updates with the latest stock price movement in the headline and the first paragraph.)</p><p>Edgewise <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (EWTX) shares rose 20% in recent Wednesday trading after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.</p><p>The company said EDG-7500 was generally well tolerated with no clinically meaningful reductions in left ventricular ejection fraction and no cases of ejection fraction drops below 50%.</p><p>Edgewise Therapeutics said it remains on track to report a full 12-week readout from part D in Q2 2026 and plans to initiate a phase 3 trial in Q4 2026.</p><p>Hypertrophic cardiomyopathy is a form of genetic heart disease.</p><p>Price: 26.01, Change: +4.27, Percent Change: +19.61</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2593640382","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593640382","pubTimestamp":1766589786,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Edgewise Therapeutics  shares rose 20% in recent Wednesday trading after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.The company said EDG-7500 was generally well tolerated with no clinically meaningful reductions in left ventricular ejection fraction and no cases of ejection fraction drops below 50%.Edgewise Therapeutics said it remains on track to report a full 12-week readout from part D in Q2 2026 and plans to initiate a phase 3 trial in Q4 2026.Hypertrophic cardiomyopathy is a form of genetic heart disease.Price: 26.01, Change: +4.27, Percent Change: +19.61","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","EWTX":"Edgewise Therapeutics, Inc.","BK4539":"次新股"},"translate_title":"更新：Edgewise Therapeutics在推进2期肥厚型心肌病试验后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EWTX":1.5},"content_text":"(Updates with the latest stock price movement in the headline and the first paragraph.)Edgewise Therapeutics (EWTX) shares rose 20% in recent Wednesday trading after the company said it completed parts B and C of a phase 2 trial of EDG-7500 in patients with obstructive and nonobstructive hypertrophic cardiomyopathy and reported favorable interim safety results from its ongoing part D study.The company said EDG-7500 was generally well tolerated with no clinically meaningful reductions in left ventricular ejection fraction and no cases of ejection fraction drops below 50%.Edgewise Therapeutics said it remains on track to report a full 12-week readout from part D in Q2 2026 and plans to initiate a phase 3 trial in Q4 2026.Hypertrophic cardiomyopathy is a form of genetic heart disease.Price: 26.01, Change: +4.27, Percent Change: +19.61","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}